AR043860A1 - Compuesto de anillo heteroaromatico de 5 miembros y su uso farmaceutico - Google Patents
Compuesto de anillo heteroaromatico de 5 miembros y su uso farmaceuticoInfo
- Publication number
- AR043860A1 AR043860A1 ARP040101228A ARP040101228A AR043860A1 AR 043860 A1 AR043860 A1 AR 043860A1 AR P040101228 A ARP040101228 A AR P040101228A AR P040101228 A ARP040101228 A AR P040101228A AR 043860 A1 AR043860 A1 AR 043860A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- optionally substituted
- atom
- alkyl
- optionally
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/28—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
Abstract
l compuesto de la presente tiene una actividad inhibidora de la proteintirosinafosfatasa 1 B superior y es útil como agente terapéutico para diabetes, complicaciones diabéticas hiperlipidemia, obesidad y similares. Reivindicación 1:Un compuesto de anillo heteroaromático de 5 miembros representado por la fórmula (1) donde V es =N- o =CH-; W es -S- u -O-; m es 0, 1 o 2; R1 y R2 son cada uno, de modo independiente, un átomo de H o un grupo alquilo C1-4; X es -N(R4)-, -N(R5)-CO-O-, -SO2-N(R5)-, -N(R5)-SO2-, -N(R6)-, -SO2-N(R5)-, -CO-N(R7)-, -N(R8)-CO-, -N(R 9 )-CO-N(R5)-, -N(R10)-(CH2)k-N(R5)-, -N(R10)-(CH2)k-N(R5)-CO-, -C(R10)=N-N(R7)-, -N(R10)-(CH2)k-CH(R6)-; -O-, -S- o -SO2- donde k es 0 o un entero de 1 a 4; R4, R5, R6, R7, R8, R9 y R10 son cada uno, de modo independiente, (1) un átomo de H, (2) un grupo alquilo C1-6 donde dicho grupo alquilo C1-6 está opcionalmente sustituido con (a) un grupo arilo opcionalmente sustituido, (b) un grupo de anillo heteroaromático opcionalmente sustituido, (c) un grupo carboxi, (d) un grupo alcoxicarbonilo C1-4, (e) -CO-N(R15)(R16) donde R15 y R16 son cada uno, de modo independiente, un átomo de H, un grupo arilo opcionalmente sustituido, un grupo de anillo heteroaromático opcionalmente sustituido, un grupo alquilo C1-6, donde dicho grupo alquilo C1-6 está opcionalmente sustituido con sustituyentes seleccionados del grupo integrado por un grupo arilo opcionalmente sustituido, un grupo de anillo heteroaromático opcionalmente sustituido, un grupo alcoxi C1-4 opcionalmente sustituido con un grupo arilo y un grupo ariloxi opcionalmente sustituido, o pueden formar un anillo indolina junto con el átomo de N unido a el, o pueden formar un anillo hetero de 5 a 7 miembros que opcionalmente contiene al menos un heteroátomo seleccionado del grupo integrado por átomo de N, átomo de O y átomo de S, (f) -N(R15)(R16) donde R15 y R16 son como se definieron con anterioridad, (g) -O-R17 donde R17 es un átomo de H, un grupo arilo opcionalmente sustituido, un grupo de anillo heteroaromático opcionalmente sustituido o un grupo alquilo C1-6, donde dicho grupo alquilo C1-6 está opcionalmente sustituido con sustituyentes seleccionados del grupo integrado por un grupo arilo opcionalmente sustituido, un grupo de anillo heteroaromático opcionalmente sustituido, un grupo alcoxi C1-4 opcionalmente sustituido con un grupo arilo y un grupo ariloxi opcionalmente sustituido, (h) -CO-R17 donde R17 es como se definió con anterioridad; (i) -SO2-R17 donde R17 es como se definió con anterioridad o (j) un grupo cicloalquilo C3-7, (3) -CO-N(R15)(R16) donde R15 y R16 son como se definieron con anterioridad, (4) -SO2-N(R15)(R16) donde R15 y R16 son como se definieron con anterioridad, (5) -CO-R17 donde R17 es como se definió con anterioridad, (6) -SO2-R17 donde R17 es como se definió con anterioridad, (7) un grupo arilo opcionalmente sustituido, (8) un grupo de anillo heteroaromático opcionalmente sustituido, o (9) R4 y R1 están opcionalmente unidos para formar un grupo de fórmula (2) donde i y j son cada uno, de modo independiente, 0, 1 o 2, (10) R5 y R9 están opcionalmente unidos para formar un grupo de fórmula (3) donde a y b son cada uno, de modo independiente, 0, 1 o 2, (11) R5 y R10 están opcionalmente unidos para formar un grupo de fórmula (4) donde k1 y c son cada uno, de modo independiente, 0 o un número entero de 1 a 4, (12) R5 y R10 están opcionalmente unidos para formar un grupo de fórmula (5) donde d y e son cada uno, de modo independiente, 0, 1 o 2, (13) R6 y R10 están opcionalmente unidos para formar un grupo de fórmula (6) donde k1 y c son como se definieron con anterioridad, o (14) R7 y R10 están opcionalmente unidos para formar un grupo de fórmula (7) donde R10´ es un átomo de H o un grupo alquilo C1-6; n es 0 o un número entero de 1 a 4; p es 0 o 1; L es (1) -C(R20)(R21)- donde R20 es (a) un átomo de H, (b) un grupo alquilo C1-6, o (c) opcionalmente unido con R4 o R8 para formar un grupo de fórmula (8) donde n1 y q son cada uno, de modo independiente, 0 o un número entero de 1 a 4, R9´ es un átomo de H, un grupo hidroxilo, un grupo alquilo C1-6, un grupo carboxi o un grupo alcoxi C1-6, o (d) opcionalmente unido con R4 para formar un grupo de fórmula (9) donde u y v son cada uno, de modo independiente, 0, 1, o 2, R21 es un átomo de H, un grupo alquilo C1-6, donde dicho grupo alquilo C1-6 está opcionalmente sustituido con un grupo arilo opcionalmente sustituido o un grupo de anillo heteroaromático opcionalmente sustituido, un grupo arilo opcionalmente sustituido o un grupo de anillo heteroaromático opcionalmente sustituido, (2) el anillo E y sus sustituyentes donde E es un grupo arilo o un grupo de anillo heteroaromático R22 es (a) un átomo de H, (b) un átomo de halógeno, (c) un grupo alquilo C1-4, (d) un grupo alcoxi C1-4 opcionalmente sustituido con un grupo carboxi, (e) un grupo alquiltio C1-6, (f) un grupo nitro, (g) -N(R23)(R24) donde R23 y R24 son cada uno, de modo independiente, un átomo de H, un grupo alquilo C1-6, un grupo alquilcarbonilo C1-4, donde dicho grupo alquilcarbonilo C1-4 está opcionalmente sustituido con un grupo amino, un grupo alquilamino C1-4 o un grupo di(alquil C1-4)amino, o un grupo alquilsulfonilo C1-4, o (h) opcionalmente unido a R4 para formar un grupo de fórmula (10) donde n2 y w son cada uno, de modo independiente, 0 o un número entero de 1 a 3, (i) opcionalmente unido con R4 para formar un grupo de fórmula (11) donde n3 y x son cada uno, de modo independiente, 0 o 1, (j) opcionalmente unido con R7 para formar un grupo de fórmula (12) donde n4 e y son cada uno, de modo independiente, 0, 1 o 2, (k) opcionalmente unido con R7 para formar un grupo de fórmula (13) donde n5 y z son cada uno, de modo independiente, 0 o 1, (l) opcionalmente unido con R8 para formar un grupo de fórmula (14) donde n2 y w son cada uno, de modo independiente, 0 o un número entero de 1 a 3, o (m) opcionalmente unido con R4 para formar un grupo de fórmula (15) o (3) el grupo de fórmula (20) donde R20, R21 y E son como se definieron con anterioridad, R25 es (a) un átomo de H, (b) un átomo de halógeno, (c) un grupo alquilo C1-4, (d) un grupo alcoxi C1-4 opcionalmente sustituido con un grupo carboxi, (e) un grupo alquiltio C1-6, (f) un grupo nitro o (g) -N(R23)(R24) donde R23 y R24 son como se definieron con anterioridad; R es -COO(R19), -A1-COO(R19) u -O-A1-COO(R19), donde A1 es un grupo alquileno C1-4 y R19 es un átomo de H o un grupo alquilo C1-4; B es un grupo arilo o un grupo de anillo heteroaromático; R3 es (1) un átomo de H, (2) un átomo de halógeno, (3) un grupo alquilo C1-8, (4) un grupo alcoxi C1-6, (5) un grupo alquilamino C1-6, (6) un grupo di(alquil C1-6)amino, (7) un grupo ciano, (8) un grupo nitro, (9) un grupo haloalquilo C1-4, (10) -S-R18, donde R18 es un grupo alquilo C1-6 o un grupo arilo, (11) -SO-R18, donde R18 es un grupo alquilo C1-6 o un grupo arilo, (12) -SO2-R18, donde R18 es un grupo alquilo C1-6 o un grupo arilo, (13) un grupo arilo o (14) un grupo heterocíclico; Y es -O-, -S-, -SO-, -SO2-, -N(R11)-, -N(R12)-CO-, -N(R12)-SO2-, -SO2-N(R12)-, -C(R13)(R14)-, -CO-, -C(R13)(R14)-N(R12)-, -CO-N(R12)- o -C(R13)(R14)-O- donde R11 es (1) un átomo de H, (2) un grupo alquilo C1-8 donde dicho alquilo C1-8 está opcionalmente sustituido con sustituyentes seleccionados del grupo integrado por (a) un grupo cicloalquilo C3-7, (b) un grupo arilo opcionalmente sustituido, (c) un grupo heterocíclico opcionalmente sustituido, (d) un grupo hidroxilo, (e) un grupo alquilamino C1-4 y (f) un grupo di(alquil C1-4)amino, (3) un grupo alquenilo C2-4, (4) un grupo alquilsulfonilo C1-4, (5) un grupo alquilcarbonilo C1-4 donde dicho grupo alquilcarbonilo C1-4 está opcionalmente sustituido con un grupo hidroxilo o un grupo alcoxi C1-4, o (6) opcionalmente unido con R3 para formar el anillo B y sus sustituyentes donde t es un número entero de 1 a 4, R12 es (1) un átomo de H, (2) un grupo alquilo C1-8 donde dicho grupo alquilo C1-8 está opcionalmente sustituido con sustituyentes seleccionados del grupo integrado por (a) un grupo cicloalquilo C3-7, (b) un grupo arilo opcionalmente sustituido, (c) un grupo heterocíclico opcionalmente sustituido, (d) un grupo hidroxilo, (e) un grupo alquilamino C1-4 y (f) un grupo di(alquil C1-4)amino, (3) un grupo alquenilo C2-4, (4) un grupo alquilsulfonilo C1-4 o (5) un grupo alquilcarbonilo C1-4 donde dicho grupo alquilcarbonilo C1-4 está opcionalmente sustituido con un grupo hidroxilo o un grupo alcoxi C1-4, R13 y R14 son cada uno, de modo independiente, un átomo de H, un grupo alquilo C1-4, o forman opcionalmente un cicloalcano C3-7 junto con el átomo de C unido a él, o forman opcionalmente, junto con el átomo de C unido a él, un anillo hetero de 5 a 7 miembros que tiene opcionalmente al menos un heteroátomo seleccionado del grupo integrado por átomo de N, átomo de O y átomo de S, con la condición de que, cuando m es 0, p es 1 y L es el grupo de fórmula (20) o un anillo E con sus sustituyentes, donde R20 y R21 son, cada uno, un átomo de H, E es un grupo fenilo, R22 es un átomo de H, un átomo de halógeno, un grupo alquilo C1-4, un grupo alcoxi C1-4 o un grupo nitro, R25 es un átomo de H, un átomo de halógeno, un grupo alquilo C1-4, un grupo alcoxi C1-4 o un grupo nitro, Y debería ser -C(R13)(R14)-N(R12)-, -CO-N(R12)- o -C(R13)(R14)-O-, donde R12, R13 y R14 son como se definieron con anterioridad; s es 0 o 1; A es un grupo alquileno C1-4 opcionalmente sustituido con un grupo cicloalquilo C3-7; Z es (1) un grupo cicloalquilo C3-7, donde dicho grupo cicloalquilo C3-7 está opcionalmente sustituido con un grupo arilo, donde dicho grupo arilo está opcionalmente sustituido con un átomo de halógeno o un grupo alquilo C1-6, o un grupo de anillo heteroaromático, donde dicho grupo de anillo heteroaromático está opcionalmente sustituido con un átomo de halógeno o un grupo alquilo C1-6, (2) un grupo arilo donde dicho grupo arilo está opcionalmente sustituido con sustituyentes seleccion
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003105267 | 2003-04-09 | ||
JP2003157590 | 2003-06-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR043860A1 true AR043860A1 (es) | 2005-08-17 |
Family
ID=33161535
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP040101228A AR043860A1 (es) | 2003-04-09 | 2004-04-12 | Compuesto de anillo heteroaromatico de 5 miembros y su uso farmaceutico |
Country Status (17)
Country | Link |
---|---|
US (1) | US20060122181A1 (es) |
EP (1) | EP1553091A4 (es) |
JP (1) | JP3819415B2 (es) |
KR (1) | KR20050119201A (es) |
AR (1) | AR043860A1 (es) |
AU (1) | AU2004228565A1 (es) |
BR (1) | BRPI0409136A (es) |
CA (1) | CA2521830A1 (es) |
CL (1) | CL2004000778A1 (es) |
CO (1) | CO5700817A2 (es) |
HK (1) | HK1078086A1 (es) |
MX (1) | MXPA05010945A (es) |
NO (1) | NO20055246L (es) |
PE (1) | PE20050018A1 (es) |
RU (1) | RU2005134659A (es) |
TW (1) | TW200500362A (es) |
WO (1) | WO2004089918A1 (es) |
Families Citing this family (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8022058B2 (en) | 2000-05-10 | 2011-09-20 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
US7879840B2 (en) | 2005-08-25 | 2011-02-01 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
US7718644B2 (en) | 2004-01-22 | 2010-05-18 | The Trustees Of Columbia University In The City Of New York | Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof |
AU2002217999A1 (en) | 2000-11-01 | 2002-05-15 | Cor Therapeutics, Inc. | Process for the production of 4-quinazolinylpiperazin-1-carboxylic acid phenylamides |
WO2003048140A1 (fr) | 2001-12-03 | 2003-06-12 | Japan Tobacco Inc. | Compose azole et utilisation medicinale de celui-ci |
WO2004010949A2 (en) | 2002-07-30 | 2004-02-05 | University Of Virginia Patent Foundation | Compounds active in spinigosine 1-phosphate signaling |
WO2005041899A2 (en) | 2003-11-03 | 2005-05-12 | University Of Virginia Patent Foundation | Orally available sphingosine 1-phosphate receptor agonists and antagonists |
US8710045B2 (en) | 2004-01-22 | 2014-04-29 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the ryanodine receptors |
BRPI0510095A (pt) | 2004-04-20 | 2007-10-16 | Transtech Pharma Inc | tiazol substituìdo e derivados de pirimidina como moduladores de receptores de melanocortina |
US7838552B2 (en) | 2004-06-04 | 2010-11-23 | Forest Laboratories Holdings Limited | Compositions comprising nebivolol |
US7803838B2 (en) | 2004-06-04 | 2010-09-28 | Forest Laboratories Holdings Limited | Compositions comprising nebivolol |
EP1780210A4 (en) * | 2004-08-11 | 2009-06-10 | Kyorin Seiyaku Kk | NEW CYCLIC AMINOBENOIC ACID DERIVATIVE |
US7645755B2 (en) * | 2004-10-22 | 2010-01-12 | Janssen Pharmaceutical N.V. | Inhibitors of c-fms kinase |
US7662837B2 (en) * | 2004-10-22 | 2010-02-16 | Janssen Pharmaceutica N.V. | Inhibitors of c-fms kinase |
KR20060058632A (ko) * | 2004-11-25 | 2006-05-30 | 주식회사 엘지생명과학 | PPAR gamma와 PPAR alpha의 활성을항진시키는 신규 화합물, 그것의 제조방법, 및 그것을함유한 약제 조성물 |
US7888527B2 (en) | 2004-12-06 | 2011-02-15 | University Of Virginia Patent Foundation | Aryl amide sphingosine 1-phosphate analogs |
AU2006214314B2 (en) | 2005-02-14 | 2012-02-09 | University Of Virginia Patent Foundation | Sphingosine 1- phos phate agonists comprising cycloalkanes and 5 -membered heterocycles substituted by amino and phenyl groups |
JP2006348024A (ja) * | 2005-05-17 | 2006-12-28 | Santen Pharmaceut Co Ltd | アミジノ誘導体を有効成分として含む神経細胞の保護剤 |
EP2119440A1 (en) * | 2005-05-17 | 2009-11-18 | Santen Pharmaceutical Co., Ltd. | Amidino derivatives for use in the prevention or treatment of retinitis pigmentosa and Leber's disease |
US20060281788A1 (en) * | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor |
US7704990B2 (en) | 2005-08-25 | 2010-04-27 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
KR20080086546A (ko) | 2006-01-27 | 2008-09-25 | 유니버시티 오브 버지니아 페이턴트 파운데이션 | 신경병증성 통증의 치료 방법 |
EP1991544B1 (en) | 2006-01-30 | 2018-08-15 | vTv Therapeutics LLC | Substituted imidazole derivatives and their use as ptpase inhibitors |
WO2007092638A1 (en) | 2006-02-09 | 2007-08-16 | University Of Virginia Patent Foundation | Bicyclic sphingosine 1-phosphate analogs |
CN101384568B (zh) * | 2006-02-15 | 2012-12-12 | 雅培制药有限公司 | 乙酰辅酶a羧化酶(acc)抑制剂及其在糖尿病、肥胖症和代谢综合征中的应用 |
JP5369257B2 (ja) * | 2006-02-15 | 2013-12-18 | アッヴィ・インコーポレイテッド | 新規なアセチル−CoAカルボキシラーゼ(ACC)阻害薬およびそれらの糖尿病、肥満および代謝症候群での使用 |
EP2021335B1 (en) | 2006-04-20 | 2011-05-25 | Janssen Pharmaceutica N.V. | Heterocyclic compounds as inhibitors of c-fms kinase |
US8697716B2 (en) | 2006-04-20 | 2014-04-15 | Janssen Pharmaceutica Nv | Method of inhibiting C-KIT kinase |
MX2008013529A (es) | 2006-04-20 | 2009-01-15 | Janssen Pharmaceutica Nv | Inhibidores de c-fms cinasa. |
WO2008033932A2 (en) * | 2006-09-13 | 2008-03-20 | The Institutes For Pharmaceutical Discovery, Llc | Biarylthiazole carboxylic acid derivatives as protein tyrosine phosphatase-ib inhibitors |
MXPA06010973A (es) * | 2006-09-25 | 2009-02-18 | World Trade Imp Export Wtie Ag | Composicion farmaceutica para el tratamiento del sobrepeso y la obesidad que se acompañan la dislipidemia. |
AU2007323540A1 (en) | 2006-11-21 | 2008-05-29 | University Of Virginia Patent Foundation | Hydrindane analogs having sphingosine 1-phosphate receptor agonist activity |
WO2008064337A2 (en) | 2006-11-21 | 2008-05-29 | University Of Virginia Patent Foundation | Benzocycloheptyl analogs having sphingosine 1-phosphate receptor activity |
CA2669102A1 (en) | 2006-11-21 | 2008-05-29 | University Of Virginia Patent Foundation | Tetralin analogs having sphingosine 1-phosphate agonist activity |
CN101260086B (zh) * | 2007-03-06 | 2011-08-10 | 中国科学院上海药物研究所 | 蛋白酪氨酸磷酸酯酶1b抑制剂及其制备方法和用途 |
AR065670A1 (es) * | 2007-03-09 | 2009-06-24 | Indigene Pharmaceuticals Inc | Combinacion de metformina r-(+) lipoato y agentes antihiperlipidemicos para el tratamiento de hiperglucemia diabetica y complicaciones diabeticas |
AR065669A1 (es) * | 2007-03-09 | 2009-06-24 | Indigene Pharmaceuticals Inc | Combinacion de metformina r-(+) lipoato y agentes antihipertensivos para el tratamiento de hiperglucemia diabetica y las complicaciones diabeticas |
KR20100017180A (ko) * | 2007-04-27 | 2010-02-16 | 닛신 파마 가부시키가이샤 | 소화성 궤양을 예방 및/또는 치료하기 위한 조성물 |
AR066379A1 (es) * | 2007-05-02 | 2009-08-12 | Boehringer Ingelheim Int | Amidas de acido carboxilico su preparacion y su uso como medicamentos |
US20090011060A1 (en) * | 2007-07-06 | 2009-01-08 | Peter Koepke | Campsiandra angustifolia extract and methods of extracting and using such extract |
US20090017140A1 (en) * | 2007-07-09 | 2009-01-15 | Peter Koepke | Maytenus abenfolia extract and methods of extracting and using such extract |
US20090035395A1 (en) * | 2007-08-01 | 2009-02-05 | Peter Koepke | Spondias mombin l. extract and methods of extracting and using such extract |
US8076491B2 (en) | 2007-08-21 | 2011-12-13 | Senomyx, Inc. | Compounds that inhibit (block) bitter taste in composition and use thereof |
NZ583350A (en) * | 2007-08-21 | 2012-03-30 | Senomyx Inc | Heteroaryl-hydantoin derivatives as bitter taste inhibitors |
US7879369B2 (en) * | 2007-09-18 | 2011-02-01 | Selvamedica, Llc | Combretum laurifolium Mart. extract and methods of extracting and using such extract |
JO3240B1 (ar) * | 2007-10-17 | 2018-03-08 | Janssen Pharmaceutica Nv | c-fms مثبطات كيناز |
EP2264017A4 (en) * | 2008-04-04 | 2011-07-27 | Takeda Pharmaceutical | Heterocyclic derivative and its use |
WO2010025142A1 (en) | 2008-08-29 | 2010-03-04 | Transtech Pharma, Inc. | Substituted aminothiazole derivatives, pharmaceutical compositions, and methods of use |
CN102264228A (zh) | 2008-10-22 | 2011-11-30 | 默沙东公司 | 用于抗糖尿病药的新的环状苯并咪唑衍生物 |
US8329914B2 (en) | 2008-10-31 | 2012-12-11 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
WO2010070617A1 (en) * | 2008-12-19 | 2010-06-24 | Shimoda Biotech (Pty) Ltd | Inclusion complexes of alpha-cyclodextrin and sildenafil salt |
US9724381B2 (en) * | 2009-05-12 | 2017-08-08 | The Administrators Of The Tulane Educational Fund | Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof |
WO2011106273A1 (en) | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
DK2624696T3 (en) * | 2010-10-06 | 2017-03-13 | Glaxosmithkline Llc Corp Service Company | BENZIMIDAZOLD DERIVATIVES AS PI3-KINASE INHIBITORS |
BR112013011188B1 (pt) | 2010-11-05 | 2022-01-04 | Senomyx, Inc | Método não-médico para modular canal potencial de receptor transiente de melastina 8 (trpm8), método não-médico para modular a sensação de resfriamento de uma composição, método não-médico para induzir uma sensação de resfriamento em um humano ou animal e composto |
CA2826649C (en) | 2011-02-25 | 2016-07-26 | Merck Sharp & Dohme Corp. | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
EP2844260A4 (en) * | 2012-04-30 | 2016-06-29 | Anderson Gaweco | ROR MODULATORS AND ITS USES |
US20140045746A1 (en) | 2012-08-02 | 2014-02-13 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
JOP20180012A1 (ar) | 2012-08-07 | 2019-01-30 | Janssen Pharmaceutica Nv | عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد |
ES2608628T3 (es) | 2012-08-07 | 2017-04-12 | Janssen Pharmaceutica Nv | Procedimiento para la preparacion de derivados de ester heterociclicos |
CN103044333A (zh) * | 2013-01-11 | 2013-04-17 | 德州翰华医药化学有限公司 | 一种高纯度奥扎格雷钠的制备方法 |
BR112015019836A2 (pt) | 2013-02-22 | 2017-07-18 | Merck Sharp & Dohme | composto, composição farmacêutica, e, uso de um composto |
US9650375B2 (en) | 2013-03-14 | 2017-05-16 | Merck Sharp & Dohme Corp. | Indole derivatives useful as anti-diabetic agents |
WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
US9326962B2 (en) | 2013-10-22 | 2016-05-03 | Steven Hoffman | Compositions and methods for treating intestinal hyperpermeability |
US10813901B2 (en) | 2013-10-22 | 2020-10-27 | Yamo Pharmaceuticals Llc | Compositions and methods for treating autism |
US10751313B2 (en) | 2013-10-22 | 2020-08-25 | Yamo Pharmaceuticals Llc | Compositions and methods for treating autism |
EP3356356B1 (en) | 2015-10-01 | 2021-05-26 | Firmenich Incorporated | Compounds useful as modulators of trpm8 |
US11072602B2 (en) | 2016-12-06 | 2021-07-27 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
EP3558298A4 (en) | 2016-12-20 | 2020-08-05 | Merck Sharp & Dohme Corp. | ANTIDIABETIC SPIROCHROMAN COMPOUNDS |
CN114292224B (zh) * | 2022-03-07 | 2022-05-20 | 中国农业科学院农产品加工研究所 | 一种大麻二酚-2-(n-乙酰基)哌啶酸酯及其应用 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5657775A (en) * | 1979-10-17 | 1981-05-20 | Takeda Chem Ind Ltd | Thiazole derivative |
DE69132006T2 (de) * | 1990-11-30 | 2000-08-03 | Otsuka Pharma Co Ltd | Thiazolederivate als inhibitoren von aktivem sauerstoff |
JP2600644B2 (ja) * | 1991-08-16 | 1997-04-16 | 藤沢薬品工業株式会社 | チアゾリルベンゾフラン誘導体 |
US6080772A (en) * | 1995-06-07 | 2000-06-27 | Sugen, Inc. | Thiazole compounds and methods of modulating signal transduction |
US5753687A (en) * | 1995-06-19 | 1998-05-19 | Ontogen Corporation | Modulators of proteins with phosphotryrosine recognition units |
US5770620A (en) * | 1995-06-19 | 1998-06-23 | Ontogen Corporation | Aryl acrylic acid derivatives useful as protein tyrosine phosphatase inhibitors |
TWI238064B (en) * | 1995-06-20 | 2005-08-21 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
FR2754258B1 (fr) * | 1996-10-08 | 1998-12-31 | Sanofi Sa | Derives d'aminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant |
US6011048A (en) * | 1997-01-28 | 2000-01-04 | Merck & Co., Inc. | Thiazole benzenesulfonamides as β3 agonists for treatment of diabetes and obesity |
US6057316A (en) * | 1998-05-12 | 2000-05-02 | American Home Products Corporation | 4-aryl-1-oxa-9-thia-cyclopenta[b]fluorenes |
US6110963A (en) * | 1998-05-12 | 2000-08-29 | American Home Products Corporation | Aryl-oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia |
US6063815A (en) * | 1998-05-12 | 2000-05-16 | American Home Products Corporation | Benzopenones useful in the treatment of insulin resistance and hyperglycemia |
US6103708A (en) * | 1998-05-12 | 2000-08-15 | American Home Products Corporation | Furans, benzofurans, and thiophenes useful in the treatment of insulin resistance and hyperglycemia |
US6110962A (en) * | 1998-05-12 | 2000-08-29 | American Home Products Corporation | 11-aryl-benzo[B]naphtho[2,3-D]furans and 11-aryl-benzo[B]naphtho[2,3-D]thiophenes useful in the treatment of insulin resistance and hyperglycemia |
CA2330558A1 (en) * | 1998-05-12 | 1999-11-18 | Wyeth | (2-acylaminothiazole-4-yl)acetic acid derivatives |
US6001867A (en) * | 1998-05-12 | 1999-12-14 | American Home Products Corporation | 1-aryl-dibenzothiophenes |
EP1083168B1 (en) * | 1998-05-25 | 2003-10-22 | Taisho Pharmaceutical Co., Ltd | Prostaglandin derivative |
US20040132788A1 (en) * | 1999-10-11 | 2004-07-08 | Chabrier De Lassauniere Pierre-Etienne | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments |
TWI292316B (en) * | 1999-10-11 | 2008-01-11 | Sod Conseils Rech Applic | Pharmaceutical composition of thiazole derivatives intended to inhibit mao and/or lipidic peroxidation and/or to act as modulators of sodium channels and the use thereof |
US7291641B2 (en) * | 1999-10-11 | 2007-11-06 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments |
JP2002114768A (ja) * | 2000-10-11 | 2002-04-16 | Japan Tobacco Inc | 2−(2,5−ジハロゲン−3,4−ジヒドロキシフェニル)アゾール化合物及びそれを含有してなる医薬組成物 |
TWI248438B (en) * | 2001-04-10 | 2006-02-01 | Sod Conseils Rech Applic | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments |
EP1446110A2 (en) * | 2001-10-16 | 2004-08-18 | Structural Bioinformatics Inc. | Organosulfur inhibitors of tyrosine phosphatases |
WO2003048140A1 (fr) * | 2001-12-03 | 2003-06-12 | Japan Tobacco Inc. | Compose azole et utilisation medicinale de celui-ci |
US6881746B2 (en) * | 2001-12-03 | 2005-04-19 | Novo Nordick A/S | Glucagon antagonists/inverse agonists |
BRPI0510095A (pt) * | 2004-04-20 | 2007-10-16 | Transtech Pharma Inc | tiazol substituìdo e derivados de pirimidina como moduladores de receptores de melanocortina |
WO2006028970A1 (en) * | 2004-09-02 | 2006-03-16 | Cengent Therapeutics, Inc. | Derivatives of thiazole and thiadiazole inhibitors of tyrosine phosphatases |
-
2004
- 2004-04-09 MX MXPA05010945A patent/MXPA05010945A/es not_active Application Discontinuation
- 2004-04-09 KR KR1020057019180A patent/KR20050119201A/ko not_active Application Discontinuation
- 2004-04-09 AU AU2004228565A patent/AU2004228565A1/en not_active Abandoned
- 2004-04-09 BR BRPI0409136-1A patent/BRPI0409136A/pt not_active IP Right Cessation
- 2004-04-09 TW TW093109862A patent/TW200500362A/zh unknown
- 2004-04-09 CA CA002521830A patent/CA2521830A1/en not_active Abandoned
- 2004-04-09 EP EP04726765A patent/EP1553091A4/en not_active Withdrawn
- 2004-04-09 JP JP2005505323A patent/JP3819415B2/ja not_active Expired - Fee Related
- 2004-04-09 WO PCT/JP2004/005119 patent/WO2004089918A1/ja not_active Application Discontinuation
- 2004-04-09 RU RU2005134659/04A patent/RU2005134659A/ru not_active Application Discontinuation
- 2004-04-12 CL CL200400778A patent/CL2004000778A1/es unknown
- 2004-04-12 AR ARP040101228A patent/AR043860A1/es not_active Application Discontinuation
- 2004-04-12 PE PE2004000360A patent/PE20050018A1/es not_active Application Discontinuation
-
2005
- 2005-07-07 US US11/176,846 patent/US20060122181A1/en not_active Abandoned
- 2005-10-28 CO CO05110118A patent/CO5700817A2/es not_active Application Discontinuation
- 2005-11-08 NO NO20055246A patent/NO20055246L/no not_active Application Discontinuation
-
2006
- 2006-01-05 HK HK06100204.6A patent/HK1078086A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
JPWO2004089918A1 (ja) | 2006-07-06 |
EP1553091A1 (en) | 2005-07-13 |
HK1078086A1 (zh) | 2006-03-03 |
NO20055246L (no) | 2005-12-21 |
TW200500362A (en) | 2005-01-01 |
US20060122181A1 (en) | 2006-06-08 |
EP1553091A4 (en) | 2007-01-17 |
MXPA05010945A (es) | 2005-11-25 |
PE20050018A1 (es) | 2005-03-23 |
AU2004228565A1 (en) | 2004-10-21 |
JP3819415B2 (ja) | 2006-09-06 |
BRPI0409136A (pt) | 2006-04-25 |
NO20055246D0 (no) | 2005-11-08 |
CL2004000778A1 (es) | 2005-01-21 |
CO5700817A2 (es) | 2006-11-30 |
RU2005134659A (ru) | 2007-05-27 |
CA2521830A1 (en) | 2004-10-21 |
KR20050119201A (ko) | 2005-12-20 |
WO2004089918A1 (ja) | 2004-10-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR043860A1 (es) | Compuesto de anillo heteroaromatico de 5 miembros y su uso farmaceutico | |
RU2386622C2 (ru) | Гетероароматические производные мочевины и их применение в качестве активаторов глюкокиназы | |
AR068538A1 (es) | Compuesto heterociclico de 5 miembros con actividad supresora de la secrecion de acido | |
CO6260132A2 (es) | Derivados de oxadiazol como inhibidores de dgat | |
ES2422204T3 (es) | Novedosos derivados de imidazolidin-2-ona como moduladores selectivos de receptor de andrógenos (SARMS) | |
AR062125A1 (es) | Compuestos que modulan el receptor cb2 y su utilizacion como medicamentos | |
AR066169A1 (es) | Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat | |
AR035548A1 (es) | Compuestos organicos | |
PE20050145A1 (es) | Dihidroquinazolinas sustituidas como agentes antivirales | |
AR018452A1 (es) | Compuestos antibioticos de oxazolidinona sustituida, proceso para su preparacion, metodo para producir un efecto antibacteriano, composicionesfarmaceuticas que los contienen y su uso para preparar medicamentos | |
AR078520A1 (es) | Compuesto heterociclico y su uso para el control de una plaga de artro-podos | |
AR043038A1 (es) | Compuestos de pirazolotriazina y usos de los mismos | |
PE20030200A1 (es) | Bencimidazol como inhibidores de las map quinasas | |
ECSP088479A (es) | Derivados de oxadiazol | |
AR077505A1 (es) | Compuestos de piridina y sus usos | |
AR083953A1 (es) | Compuestos para tratar enfermedades neurodegenerativas | |
DOP2010000194A (es) | Derivados de oxadiazol activos sobre fosfato de esfingosina-1 | |
CO6140033A2 (es) | Amino-imidazoles y su uso como medicamento para tratar discapacidad coognotiva enfermedad de alzheimer neurodegeneracion y demencia | |
AR041250A1 (es) | Derivados de sulfonamida como inhibidores de enzimas convertidoras de tnf-alfa | |
AR054024A1 (es) | Derivados de piridina -3- carboxamida como agonistas inversos de cb1 | |
AR051995A1 (es) | Derivados de tieno-piridina como intensificadores alostericos de gaba -b | |
AR107965A2 (es) | Derivados de pirimidina | |
AR060604A1 (es) | Nuevos arilamino n- heteroarilos como inhibidores de mek | |
AR052898A1 (es) | Derivados de la n-[(4,5-difenil -2-tienil) metil] amina, su preparacion, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para enfermedades mediadas por los receptores canabinoides cb1 | |
AR069813A1 (es) | Derivados de 2- amino-pirimidina, una composicion farmaceutica, un metodo de preparacion del compuesto y uso del mismo para preparar un medicamento |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |